openPR Logo
Press release

OGT aids research into molecular genetic disease

09-01-2011 07:54 AM CET | Science & Education

Press release from: Oxford Gene Technology

/ PR Agency: Alto Marketing
Unique CytoSure™ Molecular Testing Arrays provide high throughput CNV detection for multiple disorders on a single chip

Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced a new range of CytoSure™ Molecular Testing Arrays and Panels. The new DNA microarrays utilise a unique collection of probes for detecting copy number variations (CNVs) within genes associated with a variety of disorders. Three defined arrays are available covering autism and mental retardation, in-born metabolic disorders and neuromuscular dystrophy. Custom arrays can also be created by combining any of the probe sets, allowing users to specify designs that meet their experimental needs. The arrays, which have been designed in collaboration with leading molecular genetics experts at the Emory University School of Medicine, provide cost-effective testing in a flexible format, generating data that is easy to analyse using OGT’s industry-leading CytoSure Interpret Software.

Each gene on a CytoSure Molecular Testing Array is targeted via multiple exon-specific probes, thereby increasing the resolution and accuracy of CNV detection. If required, multiple diseases can be screened on a single customised array. This simplifies the workflow and reduces the time and cost of processing large, diverse sample sets.

The probes for each gene have been selected from OGT’s proprietary Oligome™ database, which contains over 23 million oligonucleotide probes optimised in silico. CytoSure Molecular Testing Arrays and Panels utilise 60 mer oligonucleotide probes in an 8 x 60k and 4 x 180k format, which has been shown to offer higher signal-to-noise ratios through increased specificity and sensitivity. Each array has been verified by Emory University School of Medicine using the CytoSure Genomic DNA Labelling Kit, ensuring there are no gaps in gene coverage and that each probe performs optimally. Further experimental validation has been performed by Emory researchers, thereby maximising the reliability and accuracy of the system. Dr Madhuri Hegde, Scientific Director at Emory Genetics Lab and assistant professor at the university and leader of the academic side of the project, commented: “Our work requires a high level of accuracy combined with in-built flexibility. OGT has the experience and expertise required to optimise the design of microarrays, which is why we chose to partner with them when developing these testing panels for use in our research.”

James Clough, OGT’s Vice President of Clinical and Genomic Solutions, said: “OGT’s new CytoSure Molecular Testing Arrays and Panels greatly simplify disease-related CNV detection. The accuracy of the approach, as well as the ease of analysis offered by OGT’s CytoSure Interpret Software, means that aberrations as small as a few kilobases can be reliably detected. The extensive automatic annotation generated by the software includes information on related syndromes, genes, exons, CNV and recombination hotspots. This provides context, turning results into insights.”

For more information about OGT’s CytoSure services and products visit www.ogt.co.uk.

About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.

CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.

Alto Marketing Limited
Office 3 | Universal Marina | Crableck Lane | Sarisbury Green | Southampton | SO31 7AL

Media enquiries
Alto Marketing Limited
Paul Avery – Science Writer
t: +44 (0)1489 557672
e: paulavery@alto-marketing.com

OGT enquiries
Oxford Gene Technology - OGT
Stephen Archibald – Marketing Communications Manager
t: +44 (0)1865 856828
e: stephen.archibald@ogt.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release OGT aids research into molecular genetic disease here

News-ID: 189979 • Views: 1086

More Releases from Oxford Gene Technology

OGT Launches New Website Providing Authoritative Resource Aiding Molecular Medic …
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has launched its brand new website. The new content-rich site provides authoritative insight into the latest developments, tools and issues in genomics research. Intuitive navigation makes it easy for users to find relevant resources matching their requirements, including insightful whitepapers and application notes, discussion topics via the new forum section, as well as detailed
OGT Hosts Successful Targeted Sequencing Workshop at ICHG/ASHG 2011
Busy seminar attracts significant interest in OGT’s Genefficiency™ genomic analysis services Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently hosted a highly successful seminar at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada. The workshop, entitled “Adding value through analysis”, was well attended and outlined how the company’s Genefficiency™ Targeted Sequencing Service can be utilised to deliver rapid
Oxford Gene Technology and Abcodia form Partnership
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced a collaborative agreement with Abcodia, a specialist company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases, aimed at improving the early detection of pancreatic cancer. As part of this collaboration, Abcodia will provide access to its large prospective serum biobank, to harness samples taken from
OGT Appoints New Finance Director
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced the appointment of a new finance director as part of the company’s ongoing rapid growth and expansion. Mr Tim Hall will join the company at the start of 2012 and brings a strong track record in financial management and strategic planning together with a broad knowledge of the biotech and healthcare

All 5 Releases


More Releases for OGT

OGT Hosts Successful Targeted Sequencing Workshop at ICHG/ASHG 2011
Busy seminar attracts significant interest in OGT’s Genefficiency™ genomic analysis services Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently hosted a highly successful seminar at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada. The workshop, entitled “Adding value through analysis”, was well attended and outlined how the company’s Genefficiency™ Targeted Sequencing Service can be utilised to deliver rapid
OGT Appoints New Finance Director
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced the appointment of a new finance director as part of the company’s ongoing rapid growth and expansion. Mr Tim Hall will join the company at the start of 2012 and brings a strong track record in financial management and strategic planning together with a broad knowledge of the biotech and healthcare
OGT to Host Workshop at ICHG/ASHG 2011
Seminar will discuss how Targeted Sequencing is being utilised to deliver rapid and cost-effective analysis of human genetic disorders. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will be discussing its new comprehensive targeted sequencing service at the International Congress of Human Genetics (ICHG) meeting in Montreal, Canada (11-15 October 2011). The conference, hosted by the American Society of Human Genetics (ASHG), will
OGT sequencing workshop at ESHG 2011 attracts over 130 delegates
Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, recently announced details of its new targeted sequencing service as part of a workshop at the European Society of Human Genetics Conference (ESHG 2011) in Amsterdam, The Netherlands. The workshop, entitled “Adding value through analysis”, attracted over 130 delegates and featured presentations from OGT team members discussing the key elements of the service. Built
Data from microarrays co-developed by OGT to be presented at ECC 2011
Talk will deliver new insights into the association of copy number variation and a range of developmental disorders Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has announced details of its upcoming workshop at the European Cytogenetics Conference 2011, held in Porto, Portugal (2–5 July). Professor Joris Vermeesch, Head of the Laboratory for Cytogenetics and Genome Research at Katholieke Universiteit Leuven will present
OGT announces new targeted next generation sequencing service
Delivering discovery, not just data Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced the release of its next generation targeted sequencing service. With an emphasis on flexibility, expert project design and advanced data analysis, the new offering takes advantage of OGT’s high-quality processes and in-house bioinformatics experience to provide the most complete targeted sequencing solution available. This includes whole exome